TB-4: Clinical Data for Unrelated Endpoints Meaningful human trial data for full-length TB-4 (corneal-healing Phase 2/3 as RGN-259, plus cardiac and wound-repair programs) Clean Phase 1 safety Cosmetic dosing is extrapolated from these programs Note: Full-length trial data does not transfer to the TB-500 fragment, so verify vial identity
Research also suggests that these injections might decrease the risk of dementia and other cognitive impairments, especially in individuals with low B12 levels
B12 keeps both body and brain sharp
Preclinical research evidence Animal Experiments Obese mouse model: After subcutaneous injection of AOD 9604 (250 g/kg) daily for 8 weeks, the body weight of obese mice decreased by 12%, the subcutaneous fat mass decreased by 25%, and the weight of epididymal adipose tissue decreased significantly
Vitamin B12 requirements fluctuate throughout the life course, influenced by metabolic demand and physiological changes
Semaglutide is best for appetite control, metabolic health, and long-term weight management